Alibaba
BABA
Cisco
CSCO
Amazon
AMZN
Adobe
ADBE
Apple
AAPL
US Stock MarketDetailed Quotes
EDIT Editas Medicine
- 1.855
- -0.155-7.71%
Trading Feb 25 15:56 ET
153.13MMarket Cap-0.73P/E (TTM)
1.980High1.800Low2.75MVolume1.920Open2.010Pre Close5.14MTurnover3.34%Turnover RatioLossP/E (Static)82.55MShares10.72952wk High0.87P/B152.52MFloat Cap1.12052wk Low--Dividend TTM82.22MShs Float99.950Historical High--Div YieldTTM8.96%Amplitude1.120Historical Low1.872Avg Price1Lot Size
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Editas Medicine Stock Forum
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
Monday, 13th January at 9:00 am
• Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia
• Achieved in vivo editing of liver cells in non-human primates and in vivo deliver...
No comment yet